GlassScriptPhysician profile
Farkad Balaya
NPI 1285679621
$2,792.01
in general payments reported to CMS, 2019-2025
15 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.25 · 2020: $76.51 · 2021: $176 · 2022: $245 · 2023: $1,873 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188 · Travel and Lodging: $866 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.62 |
| Travel and Lodging | $865.65 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,090.14 | 2023 | Solyx Sis System |
| Caldera Medical, INC | $594.19 | 2022-2023 | Desara |
| Revance Therapeutics, INC. | $320.13 | 2025 | Daxxify |
| Abbvie INC. | $256.05 | 2019-2023 | Lo Loestrin Fe |
| Astellas Pharma US INC | $197.95 | 2023 | Myrbetriq |
| Pfizer INC. | $94.77 | 2021-2023 | |
| Amgen INC. | $52.58 | 2020-2022 | |
| Octapharma USA, INC. | $40.75 | 2025 | Fibryga |
| Myovant Sciences INC. | $35.72 | 2022 | |
| Hologic Sales and Service, LLC | $28.11 | 2021 | |
| Smith+Nephew, INC. | $27.60 | 2023 | Lens 4k |
| Lupin INC. | $19.98 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $15.71 | 2021 | |
| Merck Sharp & Dohme LLC | $14.68 | 2019 | |
| Organon LLC | $3.65 | 2025 | Jada System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farkad Balaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.